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Summary
Background In this cross-sectional study, we assessed the impact of –344T>C polymorphism of the CYP11B2 gene 
which encodes aldosterone synthase on 24-hour blood pressure patterns.
Material and methods The study was performed in 137 females with essential hypertension aged 42−60 years. 
We measured plasma aldosterone level and renin activity (PRA), fasting glucose, lipid profiles and 24-hour urinary 
sodium and potassium excretion. Based on 24-hour blood pressure monitoring we identified cases with dipping and 
non-dipping patterns of blood pressure.
Results Mean PRA and aldosterone levels and aldosterone-to-renin ratio (ARR) were within normal range. Non-dip-
ping hypertension was found in 54.3% of patients. Genotype frequencies of TT, CC and CT were 27%, 27% and 
46%, respectively. Carriers of the C allele had significantly lower nocturnal blood pressure reduction (P = 0.004) 
and higher nocturnal systolic (P = 0.02) and diastolic blood pressure (P = 0.044), frequency of non-dipping profile  
(P = 0.001), and 24-hour urinary potassium excretion (P = 0.047). Urinary sodium excretion was positively correlated 
with a decrease in nocturnal blood pressure (R = 0.202; P = 0.037). In a multiple regression analysis, ARR and pres-
ence of the C allele adjusted for confounding variables were inversely associated with the nocturnal blood pressure 
decline (b = −0.348; P = 0.022 and b = −0.222; P = 0.018, respectively).
Conclusions In conclusion, in middle-aged females with essential hypertension carrying the C allele we found 
higher nocturnal blood pressure, lower nocturnal blood pressure reduction, and higher prevalence of non-dipping 
hypertension than in TT carriers.
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Background
The prevalence of hypertension in the general 
population varies from approximately from 30% 
to 45% and is strongly associated with age, gender, 
race and genetic factors [1]. Among possible mecha-
nisms underlying the development of hypertension, 
increased activity of the renin-angiotensin-aldoste-
rone system (RAAS) seems to play a crucial role 
[2–9]. It has been suggested that the RAAS activity 
might be modified by some genetic factors. Earlier 
studies demonstrated that in women aged 40−70 y e - 
ars, but not in men; polymorphism of the renin 
gene was strongly associated with the risk of hyper-
tension [10]. Other studies found the relationship 
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between polymorphism of the aldosterone synthase 
gene and hypertension [11–13]. 
Aldosterone synthase (CYP11B2) is a cytochrome 
P450 enzyme, which catalyses the terminal steps of 
aldosterone synthesis in the adrenal glands. Com-
mon variations of the CYP11B2 gene include the 
–344T>C polymorphism (substitution of thymidine 
to citosine at position –344 in the promoter re-
gion) and the C-allele of this gene polymorphism 
[11–13]. Genetic variations of the CYP11B2 gene 
which affect its expression in target organs may pre-
dispose to the development of essential hypertension 
[14], low-renin hypertension [11], left ventricular 
hypertrophy [15], and myocardial infraction [16]. 
Mitsunobua et al. demonstrated in elderly or male 
subjects derived from general Japanese population 
that the CC genotype was associated with lower 
nocturnal blood pressure and lower prevalence of 
cardiovascular disease. They suggested a beneficial 
role of this genotype in maintaining the circadian 
rhythm of blood pressure [17]. Similarly, Casiglia 
et al. found in unselected elderly population that 
systolic blood pressure was significantly lower in sub-
jects with the CC genotype, higher in the TT and 
intermediate in the CT [18]. On the other hand, 
other studies failed to demonstrate the differences 
in blood pressure between TT, CC and CT carriers 
[19]. Moreover, to our best knowledge, there have 
been no previous reports assessing the association of 
CYP11B2 polymorphisms with circadian variations 
in blood pressure. Therefore, in this study, we inves-
tigated possible associations of CYP11B2 genetic 
variations with RAAS activity and urinary sodium 
and potassium excretion rates. We were particularly 
interested in the assessment of potential impact of 
–344T>C polymorphism on blood pressure profiles 
evaluated by 24-hour monitoring.
Material and methods
Study population
The study included 137 women with primary hy-
pertension aged 42−60 years who were hospitalized 
in the Department of Hypertension and Internal 
Medicine in Szczecin. We excluded cases with con-
firmed or suspicious diagnosis of secondary hyper-
tension. 
Measurements
We measured waist circumference, height, and 
weight and calculated body mass index (BMI). All 
patients had 24-hour blood pressure monitoring 
(ABPM) (Spacelabs Healthcare) and we analysed 
systolic, diastolic, and mean blood pressure during 
the whole monitoring period, daytime, and night 
time. Non-dipping blood pressure profile was de-
fined as reduction of 0−10% in overnight blood 
pressure. PRA (normal range: 0.51−2.64 ng/ml/h) 
and plasma aldosterone (normal range: 10−160 pg/ 
/ml) were measured using commercially available 
assays. From these measurements we calculated the 
aldosterone-to-renin ratio (ARR). We also evaluat-
ed 24-hour urinary potassium (normal range: 25− 
–125 mmol/24 h) and sodium (normal range: 
40−220 mmol/24 h) excretion, lipid profiles, and 
fasting glucose.
CYP11B2 genotyping
Isolation of DNA extracted from whole blood was 
carried out by using MasterPureTM Complete DNA 
Purification kit (Epicentre Technologies; Madison, 
Wisconsin; USA), which provides the ability to ob-
tain DNA concentration of about 80 μg/ml and 
purity of 85−90%. The –344T>C polymorphism of 
CYP11B2 gene was identified by polymerase chain 
reaction-restriction fragment length polymorphism, 
as described elsewhere [20].
Statistical analysis
Descriptive data are presented as mean ± SD or 
numbers and percentage. When comparing normally 
distributed variables between groups of patients with 
CC/TC and TT genotype, an independent t test 
was used for comparing means. For compari-
son of skewedly distributed variables between the 
study groups, median values were calculated and 
Mann-Whitney U test was used. Categorical variables 
were evaluated by Chi square test. Correlations 
between nocturnal blood pressure decline and the 
study variables were evaluated by Spearman’s rank 
correlation. Multiple linear regressions including the 
presence of the C allele, ARR, BMI, age, and urine 
sodium and potassium levels predicted nocturnal 
blood pressure decline. 
Results
Genotype frequencies of TT, CC and CT were 
27%, 27% and 46%, respectively and they were 
consistent with Hardy-Weinberg equilibrium. Over-
all, frequencies of CC + CT genotypes were nearly 
three times higher than the TT genotype (Table I). 
Majority of subjects were overweight/obese and the 
mean value of waist circumference was above normal 
range. As many as 88% of patients had a positive 
family history of cardiovascular disease. Additionally, 
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Table I. Baseline characteristics of the study participants
Continuous variables Mean SD Range
Age (years) 51.87 4.92  −42 −60
Height [m] 1.61 18.44  −1.61 −1.78
Weight [kg] 77.23 0.06  −48.6 −148
Body mass index [kg/m2] 29.76 5.77  −18.6 −51.52
Waist circumference [cm] 96.17 13.78  −70 −133
24-hour systolic blood pressure [mmHg] 121.7 16.56  −110 −160
24-hour diastolic blood pressure [mmHg] 74.77 8.56  −53 −98
24-hour mean arterial pressure [mmHg] 91.82 9.68  −70 −118
Daytime systolic blood pressure [mmHg] 125.45 13.78  −97 −162
Daytime diastolic blood pressure [mmHg] 77.65 8.99  −54 −100
Daytime pulse pressure [mmHg] 47.78 8.9  −31 −82
Daytime mean arterial pressure [mmHg] 94.74 10  −73 −118
Nocturnal systolic blood pressure [mmHg] 117.1 15.24  −89 −159
Nocturnal diastolic blood pressure [mmHg] 69.12 9.32  −50 −98
Nocturnal pulse pressure [mmHg] 48.03 9.28  −31 −89
Nocturnal mean arterial pressure [mmHg] 86.34 10.82  −65 −121
Plasma renin activity [ng/ml/h] 1.88 1.75  −0.36 −12.9
Aldosterone [ng/dl] 12.37 8.36  −2.14 −58.6
Aldosterone-to-renin ratio [ng/dl per ng/ml/h] 10.61 10.72  −0.8 −99.3
Glucose [mg/dl] 96.63 15.44  −75 −189
Total cholesterol [mg/dl] 208.23 37.29  −107 −326
Low density lipoproteins [mg/dl] 123.81 31.63  −46 −218
High density lipoproteins [mg/dl] 55.09 17.8  −25 −82
Triglycerides [mg/dl] 141.42 71.81  −44 −467
Urinary sodium excretion [mmol/24 h] 140.05 63.10  −38 −359
Urinary potassium excretion [mmol/24 h] 43.93 17.41  −11.1 −92.07
Categorical variables Number Percent
Family history of cardiovascular disease 120 87.6
Smokers 38 27.7
Diabetes 22 16.0
Non-dippers 75 54.7
TT genotype 37 27.0
TC genotype 63 46.0
CC genotype 37 27.0
Data are mean ± SD or numbers (percentage)
16% had type 2 diabetes and 28% were smokers. In 
24-hour ABPM more than half of the patients had 
a non-dipping pattern of blood pressure. 
Comparisons in study parameters between CC/ 
/TC and TT (wild-type genotype) carriers are shown 
in Table II. Carriers of the C allele had significantly 
higher nocturnal blood pressure, lower blood pres-
sure reduction at night time and higher 24-hour 
urinary potassium excretion. Overall, non-dipping 
blood pressure profile was much more frequent in 
patients with CC/TC than in those with TT geno-
type. 
In all women combined, the nocturnal blood 
pressure decline was not correlated with BMI, 
waist circumference, aldosterone, PRA and urinary 
potassium excretion (Table III). There was only 
a weak positive correlation found between nocturnal 
blood pressure decline and 24-hour urine sodium 
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Table II. Comparison of groups with CYP11B2 polymorphism
Variable CYP11B2 polymorphism
TC/CC (n = 100) TT (n = 37) P value
Age (years)  51.87 ± 4.73  51.25 ± 5.51 0.558
Height [m]  1.61 ± 0.06  1.6 ± 0.05 0.423
Weight [kg]  78.15 ± 16.5  73.51 ± 11.93 0.281
Body mass index [kg/m2]  29.98 ± 5.99  28.43 ± 4.51 0.372
Waist circumference [cm]  95.49 ± 14.22  91.34 ± 10.38 0.184
24-hour systolic blood pressure [mmHg]  122.28 ± 17.47  119.42 ± 12.92 0.442
24-hour diastolic blood pressure [mmHg]  75.06 ± 8.46  74.14 ± 8.24 0.719
24-hour mean arterial pressure [mmHg]  92.33 ± 9.42  90.11 ± 9.38 0.479
Daytime systolic blood pressure [mmHg]  126.02 ± 13.56  123.51 ± 13.51 0.759
Daytime diastolic blood pressure [mmHg]  77.58 ± 8.8  78.11 ± 9.23 0.683
Daytime pulse pressure [mmHg]  48.36 ± 9.1  45.48 ± 8.07 0.314
Daytime mean arterial pressure [mmHg]  94.92 ± 9.7  94.0 ± 10.2 0.955
Nocturnal systolic blood pressure [mmHg]  119.1 ± 14.94  111.7 ± 13.41 0.022
Nocturnal diastolic blood pressure [mmHg]  70.06 ± 9.32  66.42 ± 7.95 0.044
Nocturnal pulse pressure [mmHg]  48.77 ± 9.51  45.22 ± 7.87 0.095
Nocturnal mean arterial pressure [mmHg]  87.50 ± 10.72  82.57 ± 9.29 0.034
Nocturnal blood pressure decline [mmHg]  7.4 ± 6.61  11.71 ± 6.49 0.004
Plasma renin activity [ng/ml/h]  1.83 ± 1.74  2.09 ± 1.85 0.755
Urinary sodium excretion [mmol/24 h]  140.76 ± 61.99  137.12 ± 70.02 0.796
Urinary potassium excretion [mmol/24 h]  45.37 ± 17.14  40.04 ± 84.24 0.047
Aldosterone [ng/dl]  12.84 ± 8.96  11.63 ±7.13 0.580
Aldosterone-to-renin ratio [ng/dl per ng/ml/h]  11.11 ± 11.82  9.01 ± 7.3 0.601
Glucose [mg/dl]  96.38 ± 14.4   93.34 ± 8.89 0.469
Total cholesterol [mg/dl]  209.47 ± 37.34  209.6 ± 36.1 0.661
Low density lipoproteins [mg/dl]  125.57 ± 30.86  122.37 ± 32.14 0.320
High density lipoproteins [mg/dl]  52.81 ± 15.15  62.77 ± 22.83 0.038
Triglycerides [mg/dl]  142.6 ± 72.8  131.3 ± 67.3 0.272
Dippers [n] 37 (37%) 25 (67.6%) 0.001
Non-dippers [n] 63 (63%) 12 (32.4%) 0.001
Data are mean ± SD or numbers (percentage)
Table III. Correlations of nocturnal blood pressure decline  
with measured variables
Variable R P value
Body mass index [kg/m2] −0.12 0.141
Waist circumference [cm] −0.09 0.269
Urinary sodium excretion [mmol/24 h] 0.20 0.037
Urinary potassium excretion [mmol/24 h] −0.12 0.198
Aldosterone [ng/dl] −0.01 0.837
Plasma renin activity [ng/ml/h] 0.001 0.989
Aldosterone-to-renin ratio [ng/dl per ng/ml/h] 0.004 0.956
R refers to the Spearman rank correlation coefficient
(P = 0.037). In a multiple regression analysis, ARR 
and presence of the C allele adjusted for confounding 
variables (age, BMI and urinary sodium and potas-
sium) were inversely associated with the nocturnal 
blood pressure decline (b = −0.348; P = 0.022 and 
b = −0.222; P = 0.018, respectively). In carriers of 
the C allele, a non-dipping blood pressure profile 
was positively associated with waist circumference 
(OR = 1.066; 95% CI: 1.0−1.13; P = 0.034).
Further we analysed all women in subgroups with 
high (> 120 mmol/24 h) and low (≤ 120 mmol/24 h) 
urine sodium (Table IV). We did not find significant 
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differences in frequencies of dipping and non-dip-
ping patterns of blood pressure (c2 = 0.321; P = 0.57) 
nor frequencies of CC, CT, and TT genotypes (c2 = 
= 0.386; P = 0.82). 
Discussion
In this study, we report for the first time that 
middle-aged women with essential hypertension 
who were carriers of the C allele had significantly 
higher nocturnal blood pressure, lower nocturnal 
blood pressure reduction, and higher prevalence of 
non-dipping hypertension than in TT carriers. Seve-
ral earlier studies sought associations among genetic 
variations of the CYP11B2 gene and predisposition 
to essential hypertension but they yielded inconsis-
tent results. Some authors found that T allele was 
frequent in patients with essential hypertension [18, 
21, 22], whereas in other reports the CC genotype 
and C allele frequencies were also associated with 
hypertension [23–25], including results of a large- 
-scale meta-analysis in Chinese [26]. Interestingly, 
the latter association may be significantly influenced 
by ethnicity even within the same country [26].
On the other hand, other studies demonstrated 
that the CC genotype was associated with lower 
nocturnal [17] and systemic [13, 18] blood pressure. 
Our results strongly suggest that CYP11B2 poly-
morphisms do not influence markedly the systemic 
blood pressure, but may have an impact on nocturnal 
blood pressure and the risk of non-dipping hyper-
tension. These discrepancies in the literature, besides 
of the impact of ethnicity, may be associated with 
genetic variations in the CYP11B2 gene across gen-
der [20], age [27, 28], and likely also comorbidities 
and antihypertensive treatments. In animal model, 
Chun and Siragy demonstrated that insulin-deficient 
diabetes increased, whilst lowering blood pressure 
with sartans and lowering blood glucose with insulin 
decreased renal cortical and total kidney CYP11B2 
mRNA and protein [29]. Consistently with this ob-
servation, Bellili et al. found in the general French 
population that the –344T/C polymorphism was 
associated with increased risks for incident type 2 
diabetes and metabolic syndrome [13]. Similar sug-
gestions were from study of Ichikava et al. in which 
the CT/CC carriers had increased risk of type 2 
diabetes by 40% in comparison to TT carriers [30]. 
Additionally, recent studies have emphasized that 
the aldosterone synthase CYP11B2 (–344T>C) gene 
polymorphism may be a useful predictor of the anti-
hypertensive response to valsartan [25, 29]. Hence, 
because in our series we found a high prevalence of 
type 2 diabetes and we routinely use as first-line the-
rapy for hypertension the angiotensin II receptor an-
tagonists including valsartan, we cannot exclude that 
these factors might have an impact on our results.
It has been suggested that CYP11B2 polymor-
phism might be associated with salt sensitivity of hy-
pertension [11, 31]. It has been estimated that in the 
general population this genetic variant is recognized 
in 36% of patients with salt-sensitive hypertension 
[32]. In the current study we did not assess salt-sen-
sitivity on different dietary salt regimens but only 
measured 24-hour urine sodium level, which may 
reflect, among possible many other causes, individual 
preferences to high or low sodium intake in the diet 
[33]. We did not observe significant differences in 
24-hour urinary sodium excretion between groups 
with CT/CC and TT genotypes. We only found 
a weak inverse correlation between nocturnal blood 
pressure decline and 24-hour urinary sodium excre-
tion, which was not influenced by allelic variants of 
the CYP11B2 gene. However, in the multiple regres-
sion analysis, nocturnal blood pressure decline was 
inversely associated with ARR in the presence of the 
C allele, regardless of age, BMI, and urine sodium 
and potassium levels. 
In conclusion, in middle-aged females with essen-
tial hypertension carrying the C allele we found high-
er nocturnal blood pressure, lower nocturnal blood 
pressure reduction, and higher prevalence of non-dip-
ping hypertension than in TT carriers. These findings 
suggest genetic predisposition to the development of 
blunted nocturnal blood pressure dipping and clinical 
usefulness of –344T>C polymorphism of CYP11B2 
gene in identification of patients at risk for cardiovas-
cular outcomes associated with unfavourable profile of 
the blood pressure diurnal rhythm. 
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